LAP

LAP (PF3D7_1446200) is a cytosolic, metal-dependent M17 leucyl aminopeptidase that supplies free amino acids for intra-erythrocytic P. falciparum growth by cleaving N-terminal hydrophobic residues, preferentially leucine, from hemoglobin-derived peptides (PMID:17107951, PMID:36097817). The enzyme assembles into a functionally active ~320-kDa homo-hexamer whose six active sites face inward around a central catalytic cavity, each gated by flexible loops and bearing a narrow hydrophobic S1 pocket that enforces its restricted specificity for bulky hydrophobic P1 residues (PMID:20133789, PMID:22359643). Catalysis depends on two active-site metal centers: an exchangeable site 1 (preferring Zn2+) that tunes catalytic efficiency and inhibitor binding, and a tight-binding site 2 whose loss yields an irreversibly inactive apoenzyme (PMID:19408962). Beyond catalysis, the metal ions play a structural role, driving a dynamic equilibrium between active hexamers and smaller inactive species, and a conformational switch coupling an inter-trimer loop (L13) to rearrangement of the binuclear metal center allows one active site to modulate its neighbor, providing intrinsic regulation of proteolytic rate (PMID:33303633, PMID:35691342). LAP is genetically essential and non-redundant: conditional knockdown and selective inhibition arrest parasites and produce a distinctive multiple-digestive-vacuole phenotype not seen with other hemoglobin-degrading proteases, and selective probes are lethal even before the onset of hemoglobin digestion, indicating an essential role extending beyond hemoglobin catabolism (PMID:21844374, PMID:36097817). LAP is the functional antimalarial target of bestatin and other metal-chelating inhibitors (PMID:16286469, PMID:19408962), making it a validated drug target.

1. 2005 High

   Establishing that LAP is the cellular target of the antimalarial bestatin was needed to justify it as a drug target rather than one of many parasite aminopeptidases.

   Evidence Transgenic overexpression in P. falciparum with matched enzymatic activity and inhibitor-sensitivity assays

   PMID:16286469

   Open questions at the time

   • Does not resolve whether bestatin resistance from overexpression reflects direct LAP inhibition versus buffering of enzyme pool
   • Does not establish the physiological substrate in vivo
2. 2006 High

   Reconstituting recombinant LAP defined its core biochemical identity — a metal-dependent, neutral/alkaline-optimal homo-hexamer preferring N-terminal hydrophobic residues — anchoring all later mechanistic work.

   Evidence Recombinant expression in insect cells with enzymatic assays, oligomeric sizing, and substrate profiling; localization by IHC and LAP-GFP fusion

   PMID:16286469 PMID:17107951

   Open questions at the time

   • Neutral pH optimum implies cytosolic rather than digestive-vacuole action but does not directly track physiological substrates
   • Structural basis of hexamer assembly not yet defined
3. 2009 High

   Dissecting the two active-site metal centers explained how metal identity controls catalysis and inhibitor binding, distinguishing a labile from an essential structural metal site.

   Evidence Metal chelation/reconstitution of recombinant enzyme with kinetics and bestatin binding studies

   PMID:19408962

   Open questions at the time

   • Physiological metal occupancy in the parasite cytosol not determined
   • Link between metal site and oligomeric state not yet made
4. 2010 High

   The hexameric crystal structure explained the enzyme's narrow specificity and inward-facing catalytic architecture, providing a template for inhibitor design.

   Evidence X-ray crystallography of apo and inhibitor-bound hexamer

   PMID:20133789

   Open questions at the time

   • Static structure does not capture conformational dynamics or inactive states
   • Does not address in-cell assembly regulation
5. 2011 High

   Selective activity-based inhibition showed LAP is lethal early, before hemoglobin digestion begins, implying an essential function beyond hemoglobin catabolism.

   Evidence Activity-based protein profiling with a specific probe, growth inhibition, and peptidomics

   PMID:21844374

   Open questions at the time

   • The non-hemoglobin substrate/pathway underlying early lethality is not identified
   • Does not exclude off-target probe effects on paralogs
6. 2012 High

   Systematic substrate fingerprinting quantified LAP's narrow hydrophobic preference and its dominant contribution, with PfM1AAP, to parasite aminopeptidase activity.

   Evidence Fluorogenic substrate library profiling of recombinant enzyme and native lysates

   PMID:22359643

   Open questions at the time

   • In vitro peptide substrates do not identify the physiological substrate pool
   • Functional partitioning between LAP and PfM1AAP in vivo not resolved
7. 2020 High

   Discovering that active-site metals also drive hexamer assembly revealed a structural, not merely catalytic, role for the metal centers and a dynamic oligomeric equilibrium.

   Evidence Site-directed mutagenesis, analytical ultracentrifugation, kinetics, cryo-EM and crystallography (including P. vivax ortholog for comparison)

   PMID:33303633

   Open questions at the time

   • Whether the oligomeric equilibrium is regulated in vivo is untested
   • Physiological trigger shifting the equilibrium unknown
8. 2021 High

   Fractionation, immunolocalization, and pH profiling consolidated a strictly cytosolic, neutral-pH function processing peptides exported from the digestive vacuole; cross-species profiling showed conserved hydrophobic preference but slower P. falciparum turnover.

   Evidence Cell fractionation and immunolocalization with pH-dependent kinetics; fluorogenic substrate profiling of P. falciparum, P. vivax and P. berghei orthologs

   PMID:33536500 PMID:34133730

   Open questions at the time

   • Structural-dynamicity explanation for slower turnover is proposed, not directly tested [#11]
   • Mechanism of peptide transport from digestive vacuole to cytosol not addressed
9. 2022 High

   Combined genetic knockdown and selective inhibition established that LAP is essential and non-redundant, with a distinctive multiple-digestive-vacuole phenotype; a novel inactive structure defined a metal-coupled conformational switch regulating proteolysis.

   Evidence Conditional knockdown, selective chemical inhibition, phenotypic microscopy and metabolomics; X-ray crystallography of an inactive conformation with MD simulations and mutagenesis

   PMID:35691342 PMID:36097817

   Open questions at the time

   • Mechanistic origin of the multiple-digestive-vacuole phenotype is unexplained
   • Whether the L13/metal-center switch operates as a regulatory brake in living parasites is untested
10. 2022 Low

    Increased LAP dependence in PPQ-resistant parasites tentatively links drug-resistance-driven peptide accumulation to reliance on LAP for peptide clearance.

    Evidence Pharmacological LAP inhibition in isogenic PPQ-resistant/sensitive lines with peptidomics

    PMID:36306287

    Open questions at the time

    • Mechanistic link to LAP is inferred pharmacologically, not directly probed
    • Inhibitor selectivity for LAP over other aminopeptidases in this context not confirmed
11. 2026 Low

    Screening natural-product inhibitors extended the chemical matter targeting LAP, with early-ring-stage activity and hemoglobin-metabolism perturbation.

    Evidence Enzymatic inhibition assay, phenotypic analysis, molecular docking, and metabolomics of a triterpenic phenolic ester mixture

    PMID:41484625

    Open questions at the time

    • Binding mode inferred from docking only, no structural confirmation
    • Whether phenotype is driven by LAP inhibition versus other targets not resolved

• The essential non-hemoglobin function underlying LAP's early-stage lethality, the identity of its physiological substrates, and how its metal-dependent oligomeric/conformational switching is regulated in living parasites remain unresolved.
• No physiological substrate pool defined in vivo
• Cellular basis of the multiple-digestive-vacuole phenotype unknown
• In-cell regulation of hexamer assembly and the L13 conformational switch untested